Literature DB >> 32205420

Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis.

Alexander Charles Ford1,2, Yuhong Yuan3, Paul Moayyedi3.   

Abstract

OBJECTIVES: Gastric cancer is strongly associated with Helicobacter pylori (H. pylori). We conducted a previous systematic review and meta-analysis that suggested eradication therapy reduced future incidence of gastric cancer, but effect size was uncertain, and there was no reduction in gastric cancer-related mortality. We updated this meta-analysis, as more data has accumulated. We also evaluated impact of eradication therapy on future risk of gastric cancer in patients having endoscopic mucosal resection for gastric neoplasia.
DESIGN: We searched the medical literature through February 2020 to identify randomised controlled trials (RCTs) examining effect of eradication therapy on subsequent occurrence of gastric cancer in healthy H. pylori-positive adults, and in H. pylori-positive patients with gastric neoplasia undergoing endoscopic mucosal resection. The control arm received placebo or no treatment. Follow-up was for ≥2 years. We estimated the relative risk (RR) number needed to treat (NNT), and evaluated the disability-adjusted life-years (DALYs) gained from screening from the meta-analysis.
RESULTS: We identified 10 RCTs, seven recruited 8323 healthy individuals, and three randomised 1841 patients with gastric neoplasia. In healthy individuals, eradication therapy reduced incidence of gastric cancer (RR=0.54; 95% CI 0.40 to 0.72, NNT=72), and reduced mortality from gastric cancer (RR=0.61; 95% CI 0.40 to 0.92, NNT=135), but did not affect all-cause mortality. These data suggest that 8 743 815 DALYs (95% CI 5 646 173 to 11 847 456) would be gained if population screening and treatment was implemented globally. In patients with gastric neoplasia, eradication therapy also reduced incidence of future gastric cancer (RR=0.49; 95% CI 0.34 to 0.70, NNT=21). Adverse events were incompletely reported.
CONCLUSION: There is moderate evidence to suggest that H. pylori eradication therapy reduces the incidence of gastric cancer in healthy individuals and patients with gastric neoplasia in East Asian countries. There also appears to be a reduction in gastric cancer-related mortality. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  gastric cancer; helicobacter pylori; meta-analysis

Mesh:

Substances:

Year:  2020        PMID: 32205420     DOI: 10.1136/gutjnl-2020-320839

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  37 in total

1.  A Survey of Helicobacter pylori Antibiotic-Resistant Genotypes and Strain Lineages by Whole-Genome Sequencing in China.

Authors:  Yan Zhou; Zishao Zhong; Shengjuan Hu; Jing Wang; Yanhong Deng; Ximei Li; Xianmei Chen; Xue Li; Yuanyuan Tang; Xiaofei Li; Qian Hao; Jun Liu; Tian Sang; Yang Bo; Feihu Bai
Journal:  Antimicrob Agents Chemother       Date:  2022-06-02       Impact factor: 5.938

2.  Digestive cancer screening across Europe.

Authors:  Patrizia Burra; Michael Bretthauer; Maria Buti Ferret; Ana Dugic; Pierluigi Fracasso; Marcis Leja; Tamara Matysiak Budnik; Patrick Michl; Luigi Ricciardiello; Thomas Seufferlein; Monique van Leerdam; Andreea Botos
Journal:  United European Gastroenterol J       Date:  2022-04-26       Impact factor: 6.866

3.  Effect and Safety of Helicobacter pylori Eradication Treatment Based on Molecular Pathologic Antibiotic Resistance in Chinese Elderly People.

Authors:  Chun Gao; Yan-Hua Fan
Journal:  Infect Drug Resist       Date:  2022-06-22       Impact factor: 4.177

Review 4.  Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance.

Authors:  Shamshul Ansari; Yoshio Yamaoka
Journal:  Clin Microbiol Rev       Date:  2022-04-11       Impact factor: 50.129

5.  Myths and misconceptions in the management of Helicobacter pylori infection.

Authors:  Jan Bornschein; D Mark Pritchard
Journal:  Frontline Gastroenterol       Date:  2021-07-02

6.  Microbiome and oral squamous cell carcinoma: a possible interplay on iron metabolism and its impact on tumor microenvironment.

Authors:  Rodrigo Alex Arthur; Rafael Dos Santos Bezerra; João Paulo Bianchi Ximenez; Bruna Laís Merlin; Raphael de Andrade Morraye; João Valentini Neto; Natália Melo Nasser Fava; David Livingstone Alves Figueiredo; Carlos Alberto Oliveira de Biagi; Maria Jara Montibeller; Jhefferson Barbosa Guimarães; Ellen Gomes Alves; Monique Schreiner; Tiago Silva da Costa; Charlie Felipe Liberati da Silva; Jessica Moraes Malheiros; Luan Henrique Burda da Silva; Guilherme Taborda Ribas; Daisy Obispo Achallma; Camila Margalho Braga; Karen Flaviane Assis Andrade; Valquiria do Carmo Alves Martins; Glauco Vinícius Nestor Dos Santos; Caroline Fabiane Granatto; Ulisses Costa Terin; Igor Henrique Sanches; Diana Estefania Ramos; Humberto Miguel Garay-Malpartida; Gabriela Marcelino Pereira de Souza; Svetoslav Nanev Slavov; Wilson Araújo Silva
Journal:  Braz J Microbiol       Date:  2021-05-18       Impact factor: 2.476

Review 7.  Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review.

Authors:  Pedro Cortés; Alfred D Nelson; Yan Bi; Fernando F Stancampiano; Loren P Murray; George G A Pujalte; Victoria Gomez; Dana M Harris
Journal:  J Prim Care Community Health       Date:  2021 Jan-Dec

8.  Identification of Stemness Characteristics Associated With the Immune Microenvironment and Prognosis in Gastric Cancer.

Authors:  Deli Mao; Zhijun Zhou; Shenglei Song; Dongsheng Li; Yulong He; Zhewei Wei; Changhua Zhang
Journal:  Front Oncol       Date:  2021-03-03       Impact factor: 6.244

Review 9.  Who Needs Gastroprotection in 2020?

Authors:  Takeshi Kanno; Paul Moayyedi
Journal:  Curr Treat Options Gastroenterol       Date:  2020-11-11

10.  Unraveling the Novel Effect of Patchouli Alcohol Against the Antibiotic Resistance of Helicobacter pylori.

Authors:  Yuanzun Zhong; Liyao Tang; Qiuhua Deng; Li Jing; Jiao Zhang; Yao Zhang; Feng Yu; Yijun Ou; Shaoju Guo; Bin Huang; Hongying Cao; Ping Huang; Yifei Xu
Journal:  Front Microbiol       Date:  2021-06-02       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.